AIM: To determine the efficacy of Mac-2 binding protein (Mac-2bp) for diagnosis of chronic pancreatitis. METHODS: Fifty-nine healthy volunteers (HV), 162 patients with chronic pancreatitis (CP), and 94 patients with pancreatic ductal adenocarcinoma (PDAC) were enrolled in this study. We measured serum Mac-2bp using our developed enzyme-linked immunosorbent assay kit. Additional biochemical variables were measured using an automated analyzer (including aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, triglyceride, C-reactive protein, and amylase levels) or chemiluminescent enzyme immunoassay (carbohydrate antigen 19-9 and carcinoembryonic antigen). The ability of Mac-2bp to predict CP diagnosis accurately was assessed using receiver operating characteristic (ROC) analyses. RESULTS: Serum Mac-2bp levels were significantly increased in CP patients compared to HV (P < 0.0001) and PDAC patients (P < 0.0001). Area under the ROC curve values of Mac-2bp for the discrimination of CP from HV and PDAC were 0.727 and 0.784, respectively. Multivariate analyses demonstrated that serum Mac-2bp levels were independent determinants for CP diagnosis from HV and PDAC patients. Immunohistological staining showed that Mac-2bp was expressed faintly in the pancreas tissues of both CP and PDAC patients. Serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, and triglyceride levels were significantly higher in patients with CP or PDAC. Serum Mac-2bp levels were highly correlated with protein levels of alanine aminotransferase, γ-glutamyltransferase, and C-reactive protein, but not amylase, suggesting that the damaged liver produces Mac-2bp. CONCLUSION: Measurement of serum Mac-2bp may be a novel and useful biomarker for CP diagnosis as well as liver fibrosis in the general population.
AIM: To determine the efficacy of Mac-2 binding protein (Mac-2bp) for diagnosis of chronic pancreatitis. METHODS: Fifty-nine healthy volunteers (HV), 162 patients with chronic pancreatitis (CP), and 94 patients with pancreatic ductal adenocarcinoma (PDAC) were enrolled in this study. We measured serum Mac-2bp using our developed enzyme-linked immunosorbent assay kit. Additional biochemical variables were measured using an automated analyzer (including aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, triglyceride, C-reactive protein, and amylase levels) or chemiluminescent enzyme immunoassay (carbohydrate antigen 19-9 and carcinoembryonic antigen). The ability of Mac-2bp to predict CP diagnosis accurately was assessed using receiver operating characteristic (ROC) analyses. RESULTS: Serum Mac-2bp levels were significantly increased in CP patients compared to HV (P < 0.0001) and PDACpatients (P < 0.0001). Area under the ROC curve values of Mac-2bp for the discrimination of CP from HV and PDAC were 0.727 and 0.784, respectively. Multivariate analyses demonstrated that serum Mac-2bp levels were independent determinants for CP diagnosis from HV and PDACpatients. Immunohistological staining showed that Mac-2bp was expressed faintly in the pancreas tissues of both CP and PDACpatients. Serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, and triglyceride levels were significantly higher in patients with CP or PDAC. Serum Mac-2bp levels were highly correlated with protein levels of alanine aminotransferase, γ-glutamyltransferase, and C-reactive protein, but not amylase, suggesting that the damaged liver produces Mac-2bp. CONCLUSION: Measurement of serum Mac-2bp may be a novel and useful biomarker for CP diagnosis as well as liver fibrosis in the general population.
Authors: Erwin-Jan M van Geenen; Mark M Smits; Tim C M A Schreuder; Donald L van der Peet; Elisabeth Bloemena; Chris J J Mulder Journal: Pancreas Date: 2010-11 Impact factor: 3.327
Authors: Zobeida Cruz-Monserrate; Kristyn Gumpper; Valentina Pita; Phil A Hart; Christopher Forsmark; David C Whitcomb; Dhiraj Yadav; Richard T Waldron; Stephen Pandol; Hanno Steen; Vincent Anani; Natasha Kanwar; Santhi Swaroop Vege; Savi Appana; Liang Li; Jose Serrano; Jo Ann S Rinaudo; Mark Topazian; Darwin L Conwell Journal: Pancreatology Date: 2021-01-22 Impact factor: 3.996
Authors: Michael M Mendelson; Riccardo E Marioni; Roby Joehanes; Chunyu Liu; Åsa K Hedman; Stella Aslibekyan; Ellen W Demerath; Weihua Guan; Degui Zhi; Chen Yao; Tianxiao Huan; Christine Willinger; Brian Chen; Paul Courchesne; Michael Multhaup; Marguerite R Irvin; Ariella Cohain; Eric E Schadt; Megan L Grove; Jan Bressler; Kari North; Johan Sundström; Stefan Gustafsson; Sonia Shah; Allan F McRae; Sarah E Harris; Jude Gibson; Paul Redmond; Janie Corley; Lee Murphy; John M Starr; Erica Kleinbrink; Leonard Lipovich; Peter M Visscher; Naomi R Wray; Ronald M Krauss; Daniele Fallin; Andrew Feinberg; Devin M Absher; Myriam Fornage; James S Pankow; Lars Lind; Caroline Fox; Erik Ingelsson; Donna K Arnett; Eric Boerwinkle; Liming Liang; Daniel Levy; Ian J Deary Journal: PLoS Med Date: 2017-01-17 Impact factor: 11.069
Authors: M Gordian Adam; Georg Beyer; Julia Mayerle; Markus M Lerch; Nicole Christiansen; Beate Kamlage; Christian Pilarsky; Marius Distler; Tim Fahlbusch; Ansgar Chromik; Fritz Klein; Marcus Bahra; Waldemar Uhl; Robert Grützmann; Ujjwal M Mahajan; Frank U Weiss Journal: Gut Date: 2021-02-04 Impact factor: 23.059